tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Uveomeningoencephalitic Syndrome D014607 1 associated lipids
Lupus Erythematosus, Discoid D008179 1 associated lipids
Cervical Intraepithelial Neoplasia D018290 1 associated lipids
Cardiovirus Infections D018188 3 associated lipids
Fungemia D016469 2 associated lipids
Legionellosis D007876 3 associated lipids
Lung Abscess D008169 1 associated lipids
IgA Deficiency D017098 2 associated lipids
IgG Deficiency D017099 1 associated lipids
Hepatic Veno-Occlusive Disease D006504 1 associated lipids
Alopecia Areata D000506 6 associated lipids
Anemia, Refractory, with Excess of Blasts D000754 2 associated lipids
Hepatitis, Autoimmune D019693 1 associated lipids
Intestinal Fistula D007412 1 associated lipids
Polyendocrinopathies, Autoimmune D016884 1 associated lipids
Meningitis, Cryptococcal D016919 1 associated lipids
Polymyositis D017285 1 associated lipids
Uveitis, Posterior D015866 5 associated lipids
Red-Cell Aplasia, Pure D012010 4 associated lipids
Smooth Muscle Tumor D018235 1 associated lipids
Blepharitis D001762 4 associated lipids
Hearing Loss, Sudden D003639 1 associated lipids
Trichomonas Vaginitis D014247 2 associated lipids
Hypopigmentation D017496 2 associated lipids
Pemphigoid, Benign Mucous Membrane D010390 4 associated lipids
Feline Acquired Immunodeficiency Syndrome D016181 1 associated lipids
Cryptogenic Organizing Pneumonia D018549 3 associated lipids
Amputation, Traumatic D000673 2 associated lipids
Erythema Nodosum D004893 5 associated lipids
Sweet Syndrome D016463 1 associated lipids
Pyoderma Gangrenosum D017511 3 associated lipids
Nervous System Autoimmune Disease, Experimental D020721 3 associated lipids
Deglutition Disorders D003680 2 associated lipids
Oral Ulcer D019226 1 associated lipids
Immunoblastic Lymphadenopathy D007119 2 associated lipids
Leukemia, Myeloid, Chronic-Phase D015466 1 associated lipids
Lupus Erythematosus, Cutaneous D008178 2 associated lipids
Dental Enamel Hypoplasia D003744 2 associated lipids
Fasciitis, Necrotizing D019115 1 associated lipids
Cutis Laxa D003483 1 associated lipids
Rotavirus Infections D012400 1 associated lipids
Epididymitis D004823 1 associated lipids
Orchitis D009920 1 associated lipids
Ichthyosiform Erythroderma, Congenital D016113 1 associated lipids
Polyomavirus Infections D027601 1 associated lipids
Citrullinemia D020159 1 associated lipids
Eye Infections, Viral D015828 1 associated lipids
Hand Injuries D006230 1 associated lipids
Pseudohypoaldosteronism D011546 1 associated lipids
Lichen Planus, Oral D017676 2 associated lipids
Flaviviridae Infections D018178 1 associated lipids
Megacolon, Toxic D008532 1 associated lipids
Lichen Sclerosus et Atrophicus D018459 2 associated lipids
Leukemia, Biphenotypic, Acute D015456 2 associated lipids
Lichenoid Eruptions D017512 1 associated lipids
Herpes Labialis D006560 1 associated lipids
Pemphigus D010392 3 associated lipids
Mutism D009155 1 associated lipids
Neurodermatitis D009450 1 associated lipids
Leukoplakia, Oral D007972 1 associated lipids
Hypertensive Encephalopathy D020343 1 associated lipids
Skin Diseases, Viral D017193 2 associated lipids
Cytomegalovirus Retinitis D017726 2 associated lipids
Rectal Fistula D012003 2 associated lipids
Vestibular Diseases D015837 2 associated lipids
Intestinal Atresia D007409 3 associated lipids
Priapism D011317 1 associated lipids
Kaposi Varicelliform Eruption D007617 1 associated lipids
Echinostomiasis D004451 1 associated lipids
Respiratory Tract Neoplasms D012142 2 associated lipids
Trichomonas Infections D014245 3 associated lipids
Deltaretrovirus Infections D006800 1 associated lipids
West Nile Fever D014901 1 associated lipids
Foot Ulcer D016523 4 associated lipids
Fibroadenoma D018226 2 associated lipids
Tinea Capitis D014006 1 associated lipids
Pancreatic Fistula D010185 2 associated lipids
Facial Nerve Injuries D020220 1 associated lipids
Lymphocele D008210 1 associated lipids
End Stage Liver Disease D058625 1 associated lipids
Thrombotic Microangiopathies D057049 1 associated lipids
Angiofibroma D018322 2 associated lipids
Posterior Leukoencephalopathy Syndrome D054038 1 associated lipids
Peroneal Neuropathies D020427 1 associated lipids
Hearing Loss, Bilateral D006312 1 associated lipids
Cheilitis D002613 2 associated lipids
Still's Disease, Adult-Onset D016706 2 associated lipids
Hidradenitis Suppurativa D017497 2 associated lipids
Lymphocytic Choriomeningitis D008216 1 associated lipids
Necrobiosis Lipoidica D009335 2 associated lipids
Vulvar Lichen Sclerosus D007724 1 associated lipids
Neuromyelitis Optica D009471 2 associated lipids
Optic Neuritis D009902 1 associated lipids
Dysplastic Nevus Syndrome D004416 1 associated lipids
Epidermolysis Bullosa D004820 3 associated lipids
Dendritic Cell Sarcoma, Interdigitating D054739 1 associated lipids
Epidermolysis Bullosa Dystrophica D016108 1 associated lipids
Churg-Strauss Syndrome D015267 2 associated lipids
Myelinolysis, Central Pontine D017590 1 associated lipids
Balanitis D001446 4 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Ruzicka T et al. Tacrolimus: the drug for the turn of the millennium? 1999 Arch Dermatol pmid:10328199
Qureshi AA and Fischer MA Topical calcineurin inhibitors for atopic dermatitis: balancing clinical benefit and possible risks. 2006 Arch Dermatol pmid:16702502
Systemic tacrolimus (FK 506) is effective for the treatment of psoriasis in a double-blind, placebo-controlled study. The European FK 506 Multicentre Psoriasis Study Group. 1996 Arch Dermatol pmid:8629845
Van Leent EJ et al. Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis. 1998 Arch Dermatol pmid:9681343
Mandelin J et al. Effect of oral acetylsalicylic acid on burning caused by tacrolimus ointment in patients with atopic dermatitis. 2010 Arch Dermatol pmid:20956662
Passeron T et al. Topical tacrolimus and the 308-nm excimer laser: a synergistic combination for the treatment of vitiligo. 2004 Arch Dermatol pmid:15381545
Bunker CB et al. Topical tacrolimus, genital lichen sclerosus, and risk of squamous cell carcinoma. 2004 Arch Dermatol pmid:15381566
Ehst BD and Warshaw EM Alcohol-induced application site erythema after topical immunomodulator use and its inhibition by aspirin. 2004 Arch Dermatol pmid:15313828
Sagransky MJ et al. A randomized controlled pilot study of the effects of an extra office visit on adherence and outcomes in atopic dermatitis. 2010 Arch Dermatol pmid:21173330
Laino L and DiCarlo A Palmoplantar pustular psoriasis: clinical and video thermographic evaluation before and after topical tacrolimus treatment. 2011 Arch Dermatol pmid:21690553
Eiling E et al. Pimecrolimus: a novel treatment for cetuximab-induced papulopustular eruption. 2008 Arch Dermatol pmid:18794482
Byrd JA et al. Response of oral lichen planus to topical tacrolimus in 37 patients. 2004 Arch Dermatol pmid:15611431
Santos-Juanes J et al. Topical tacrolimus: an effective therapy for Zoon balanitis. 2004 Arch Dermatol pmid:15611442
Milingou M et al. Alcohol intolerance and facial flushing in patients treated with topical tacrolimus. 2004 Arch Dermatol pmid:15611445
Yan AC et al. The safety and efficacy of pimecrolimus, 1%, cream for the treatment of Netherton syndrome: results from an exploratory study. 2010 Arch Dermatol pmid:20083693
Ciurea AM et al. Complete and durable clinical response of malignant pyoderma to tacrolimus in combination with dapsone and prednisone. 2010 Arch Dermatol pmid:20083712
Mikhail M et al. Rapid enlargement of a malignant melanoma in a child with vitiligo vulgaris after application of topical tacrolimus. 2008 Arch Dermatol pmid:18427063
Böhm M et al. Successful treatment of anogenital lichen sclerosus with topical tacrolimus. 2003 Arch Dermatol pmid:12873890
Reitamo S et al. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. The European Tacrolimus Ointment Study Group. 2000 Arch Dermatol pmid:10926735
Allen DM and Esterly NB Significant systemic absorption of tacrolimus after topical application in a patient with lamellar ichthyosis. 2002 Arch Dermatol pmid:12225004
Okudaira H et al. Control of allergic diseases by regulation of cytokine gene transcription. 1997 Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M pmid:9383912
Pavan M et al. Polyomavirus associated nephropathy presenting five years after kidney transplantation. 2011 Arab J Nephrol Transplant pmid:21999857
Barreiro C and Martínez-Castro M Trends in the biosynthesis and production of the immunosuppressant tacrolimus (FK506). 2014 Appl. Microbiol. Biotechnol. pmid:24272367
Salehi-Najafabadi Z et al. The gamma-butyrolactone receptors BulR1 and BulR2 of Streptomyces tsukubaensis: tacrolimus (FK506) and butyrolactone synthetases production control. 2014 Appl. Microbiol. Biotechnol. pmid:24562179
Kimura T et al. N-glycosylation is involved in the sensitivity of Saccharomyces cerevisiae to HM-1 killer toxin secreted from Hansenula mrakii IFO 0895. 1999 Appl. Microbiol. Biotechnol. pmid:10091323
Song K et al. Engineering of the LysR family transcriptional regulator FkbR1 and its target gene to improve ascomycin production. 2017 Appl. Microbiol. Biotechnol. pmid:28349163
Mo S et al. Application of a combined approach involving classical random mutagenesis and metabolic engineering to enhance FK506 production in Streptomyces sp. RM7011. 2013 Appl. Microbiol. Biotechnol. pmid:23053074
Wang J et al. Comparative proteomic and metabolomic analysis of Streptomyces tsukubaensis reveals the metabolic mechanism of FK506 overproduction by feeding soybean oil. 2017 Appl. Microbiol. Biotechnol. pmid:28175948
Ordóñez-Robles M et al. Target genes of the Streptomyces tsukubaensis FkbN regulator include most of the tacrolimus biosynthesis genes, a phosphopantetheinyl transferase and other PKS genes. 2016 Appl. Microbiol. Biotechnol. pmid:27357227
Salehi-Najafabadi Z et al. Characterisation of a γ-butyrolactone receptor of Streptomyces tacrolimicus: effect on sporulation and tacrolimus biosynthesis. 2011 Appl. Microbiol. Biotechnol. pmid:21792593
Ma D et al. Manipulating the expression of SARP family regulator BulZ and its target gene product to increase tacrolimus production. 2018 Appl. Microbiol. Biotechnol. pmid:29666890
Ordóñez-Robles M et al. Streptomyces tsukubaensis as a new model for carbon repression: transcriptomic response to tacrolimus repressing carbon sources. 2017 Appl. Microbiol. Biotechnol. pmid:28983826
Kim DH et al. Mutational biosynthesis of tacrolimus analogues by fkbO deletion mutant of Streptomyces sp. KCTC 11604BP. 2013 Appl. Microbiol. Biotechnol. pmid:23392766
Martínez-Castro M et al. Taxonomy and chemically semi-defined media for the analysis of the tacrolimus producer 'Streptomyces tsukubaensis'. 2013 Appl. Microbiol. Biotechnol. pmid:22990582
Chen D et al. Improvement of FK506 production in Streptomyces tsukubaensis by genetic enhancement of the supply of unusual polyketide extender units via utilization of two distinct site-specific recombination systems. 2012 Appl. Environ. Microbiol. pmid:22582065
Mo S et al. Roles of fkbN in positive regulation and tcs7 in negative regulation of FK506 biosynthesis in Streptomyces sp. strain KCTC 11604BP. 2012 Appl. Environ. Microbiol. pmid:22267670
Kallscheuer N et al. Single-Domain Peptidyl-Prolyl cis/trans Isomerase FkpA from Corynebacterium glutamicum Improves the Biomass Yield at Increased Growth Temperatures. 2015 Appl. Environ. Microbiol. pmid:26341203
Kuo WW et al. Cardiomyoblast apoptosis induced by insulin-like growth factor (IGF)-I resistance is IGF-II dependent and synergistically enhanced by angiotensin II. 2006 Apoptosis pmid:16699953
Rapak A et al. Apoptosis of lymphoma cells is abolished due to blockade of cytochrome c release despite Nur77 mitochondrial targeting. 2007 Apoptosis pmid:17701362
Kabat-Koperska J et al. The influence of exposure to immunosuppressive treatment during pregnancy on renal function and rate of apoptosis in native kidneys of female Wistar rats. 2016 Apoptosis pmid:27586504
Kemper K et al. Targeting colorectal cancer stem cells with inducible caspase-9. 2012 Apoptosis pmid:22223359
Ginestà MM et al. Acute xenograft rejection, late xenograft rejection and long term survival xenografts in the hamster-to-rat heart transplantation model: histological characterisation under low-dose of FK506. 2002 APMIS pmid:12583441
Pea F et al. Drop in trough blood concentrations of tacrolimus after switching from nelfinavir to fosamprenavir in four HIV-infected liver transplant patients. 2008 Antivir. Ther. (Lond.) pmid:18771060
Gauthier C et al. Functional similarities and differences between Candida albicans Cdr1p and Cdr2p transporters. 2003 Antimicrob. Agents Chemother. pmid:12709320
Del Poeta M et al. Synergistic antifungal activities of bafilomycin A(1), fluconazole, and the pneumocandin MK-0991/caspofungin acetate (L-743,873) with calcineurin inhibitors FK506 and L-685,818 against Cryptococcus neoformans. 2000 Antimicrob. Agents Chemother. pmid:10681348
Steinbach WJ et al. Calcineurin inhibition or mutation enhances cell wall inhibitors against Aspergillus fumigatus. 2007 Antimicrob. Agents Chemother. pmid:17502415
Gao L et al. Synergistic Effects of Tacrolimus and Azoles against Exophiala dermatitidis. 2017 Antimicrob. Agents Chemother. pmid:28923863
Morikawa K et al. Immunomodulatory effects of three macrolides, midecamycin acetate, josamycin, and clarithromycin, on human T-lymphocyte function in vitro. 1994 Antimicrob. Agents Chemother. pmid:7532933
Steinbach WJ et al. In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus. 2004 Antimicrob. Agents Chemother. pmid:15105118
Onyewu C et al. Targeting the calcineurin pathway enhances ergosterol biosynthesis inhibitors against Trichophyton mentagrophytes in vitro and in a human skin infection model. 2007 Antimicrob. Agents Chemother. pmid:17664323
Lamoth F et al. In vitro activity of calcineurin and heat shock protein 90 Inhibitors against Aspergillus fumigatus azole- and echinocandin-resistant strains. 2013 Antimicrob. Agents Chemother. pmid:23165466
Onyewu C et al. Ergosterol biosynthesis inhibitors become fungicidal when combined with calcineurin inhibitors against Candida albicans, Candida glabrata, and Candida krusei. 2003 Antimicrob. Agents Chemother. pmid:12604527
Fortwendel JR et al. Differential effects of inhibiting chitin and 1,3-{beta}-D-glucan synthesis in ras and calcineurin mutants of Aspergillus fumigatus. 2009 Antimicrob. Agents Chemother. pmid:19015336
Lamping E et al. Abc1p is a multidrug efflux transporter that tips the balance in favor of innate azole resistance in Candida krusei. 2009 Antimicrob. Agents Chemother. pmid:19015352
Reedy JL et al. Immunotherapy with tacrolimus (FK506) does not select for resistance to calcineurin inhibitors in Candida albicans isolates from liver transplant patients. 2006 Antimicrob. Agents Chemother. pmid:16569889
Katiyar SK et al. Fks1 and Fks2 are functionally redundant but differentially regulated in Candida glabrata: implications for echinocandin resistance. 2012 Antimicrob. Agents Chemother. pmid:23027185
Vaes M et al. Therapeutic drug monitoring of posaconazole in patients with acute myeloid leukemia or myelodysplastic syndrome. 2012 Antimicrob. Agents Chemother. pmid:23027198
Morikawa K et al. Immunosuppressive activity of fosfomycin on human T-lymphocyte function in vitro. 1993 Antimicrob. Agents Chemother. pmid:7509146
Zhuang D et al. Effect of calcineurin inhibitors on posaconazole blood levels as measured by the MVista microbiological assay. 2008 Antimicrob. Agents Chemother. pmid:18025114
Sun S et al. In vitro interactions between tacrolimus and azoles against Candida albicans determined by different methods. 2008 Antimicrob. Agents Chemother. pmid:18056277
Kontoyiannis DP et al. Calcineurin inhibitor agents interact synergistically with antifungal agents in vitro against Cryptococcus neoformans isolates: correlation with outcome in solid organ transplant recipients with cryptococcosis. 2008 Antimicrob. Agents Chemother. pmid:18070977
Hashemizadeh Z et al. Observational Study of Associations between Voriconazole Therapeutic Drug Monitoring, Toxicity, and Outcome in Liver Transplant Patients. 2017 Antimicrob. Agents Chemother. pmid:28923870
Ricardo E et al. In vivo and in vitro acquisition of resistance to voriconazole by Candida krusei. 2014 Antimicrob. Agents Chemother. pmid:24867987
Coilly A et al. Practical management of boceprevir and immunosuppressive therapy in liver transplant recipients with hepatitis C virus recurrence. 2012 Antimicrob. Agents Chemother. pmid:22908172
Gao L and Sun Y In vitro interactions of antifungal agents and tacrolimus against Aspergillus biofilms. 2015 Antimicrob. Agents Chemother. pmid:26303797
Uppuluri P et al. Synergistic effect of calcineurin inhibitors and fluconazole against Candida albicans biofilms. 2008 Antimicrob. Agents Chemother. pmid:18180354
Odom A et al. The immunosuppressant FK506 and its nonimmunosuppressive analog L-685,818 are toxic to Cryptococcus neoformans by inhibition of a common target protein. 1997 Antimicrob. Agents Chemother. pmid:8980772
Roy J et al. The immunosuppressant rapamycin represses human immunodeficiency virus type 1 replication. 2002 Antimicrob. Agents Chemother. pmid:12384349
Steinbach WJ et al. In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus isolates from transplant and nontransplant patients. 2004 Antimicrob. Agents Chemother. pmid:15561883
Sugita T et al. A new calcineurin inhibitor, pimecrolimus, inhibits the growth of Malassezia spp. 2006 Antimicrob. Agents Chemother. pmid:16870799
Dang W et al. Inhibition of Calcineurin or IMP Dehydrogenase Exerts Moderate to Potent Antiviral Activity against Norovirus Replication. 2017 Antimicrob. Agents Chemother. pmid:28807916
Aoki Y and Kao PN Erythromycin inhibits transcriptional activation of NF-kappaB, but not NFAT, through calcineurin-independent signaling in T cells. 1999 Antimicrob. Agents Chemother. pmid:10543746
Dannaoui E et al. In vitro interactions between antifungals and immunosuppressive drugs against zygomycetes. 2009 Antimicrob. Agents Chemother. pmid:19451295
Rivosecchi RM et al. Effects of Isavuconazole on the Plasma Concentrations of Tacrolimus among Solid-Organ Transplant Patients. 2017 Antimicrob. Agents Chemother. pmid:28674051
Rosenwirth B et al. Inhibition of human immunodeficiency virus type 1 replication by SDZ NIM 811, a nonimmunosuppressive cyclosporine analog. 1994 Antimicrob. Agents Chemother. pmid:7527198
Venkataramanan R et al. Voriconazole inhibition of the metabolism of tacrolimus in a liver transplant recipient and in human liver microsomes. 2002 Antimicrob. Agents Chemother. pmid:12183280
Mizuno K et al. Modulation of multidrug resistance by immunosuppressive agents: cyclosporin analogues, FK506 and mizoribine. 1992 Jan-Feb Anticancer Res. pmid:1373592
Pinsk V et al. Complete Reversion of Familial Adenomatous Polyposis Phenotype Associated with Tacrolimus and Mycophenolate Mofetil Treatment Following Kidney Transplantation. 2017 Anticancer Res. pmid:28551651
Kalas W et al. FK506 restores sensitivity of thymic lymphomas to calcium-mediated apoptosis and the inducible expression of Fas ligand. 2003 Mar-Apr Anticancer Res. pmid:12820430
Harada N et al. Serum Asunaprevir and Daclatasvir Concentrations and Outcomes in Patients with Recurrent Hepatitis C Who Have Undergone Living Donor Liver Transplantation. 2018 Anticancer Res. pmid:30194210
Ling G et al. Mycophenolate Mofetil Alone and in Combination with Tacrolimus Inhibits the Proliferation of HT-29 Human Colonic Adenocarcinoma Cell Line and Might Interfere with Colonic Tumorigenesis. 2018 Anticancer Res. pmid:29848681
Morisaki T et al. A combination of cyclosporin-A (CsA) and interferon-gamma (INF-gamma) induces apoptosis in human gastric carcinoma cells. 2000 Sep- Oct Anticancer Res. pmid:11131636
Gornet JM et al. Severe CPT-11-induced diarrhea in presence of FK-506 following liver transplantation for hepatocellular carcinoma. 2001 Nov-Dec Anticancer Res. pmid:11911319
Jachez B et al. Reversion of the P-glycoprotein-mediated multidrug resistance of cancer cells by FK-506 derivatives. 1993 Anticancer Drugs pmid:7683935
Yamamoto M et al. Cyclosporin A and FK506 reverse anthracycline resistance by altering the cell cycle. 1995 Anticancer Drugs pmid:7579561
Pourtier-Manzanedo A et al. FK-506 (fujimycin) reverses the multidrug resistance of tumor cells in vitro. 1991 Anticancer Drugs pmid:1724925
Epand RF and Epand RM The new potent immunosuppressant FK-506 reverses multidrug resistance in Chinese hamster ovary cells. 1991 Anticancer Drug Des. pmid:1714737
Romano S et al. FK506 binding proteins as targets in anticancer therapy. 2010 Anticancer Agents Med Chem pmid:21182472
Nikitin AV [Mechanisms of nephrotoxic action of immunodepressants, calcineurine inhibitors]. 2014 Antibiot. Khimioter. pmid:25051716
Pratt WB The role of the hsp90-based chaperone system in signal transduction by nuclear receptors and receptors signaling via MAP kinase. 1997 Annu. Rev. Pharmacol. Toxicol. pmid:9131255
Tzakis AG et al. Intestinal transplantation. 1994 Annu. Rev. Med. pmid:7515221
Hanauer SB and Dassopoulos T Evolving treatment strategies for inflammatory bowel disease. 2001 Annu. Rev. Med. pmid:11160781
Sigal NH and Dumont FJ Cyclosporin A, FK-506, and rapamycin: pharmacologic probes of lymphocyte signal transduction. 1992 Annu. Rev. Immunol. pmid:1375473
Schmid FX Prolyl isomerase: enzymatic catalysis of slow protein-folding reactions. 1993 Annu Rev Biophys Biomol Struct pmid:7688608
Holechek MJ Medication review: FK 506. 1991 ANNA J pmid:1708982
Aguiar D et al. Real-World Multicenter Experience of Immunosuppression Minimization Among 661 Liver Transplant Recipients. 2017 Ann. Transplant. pmid:28461684
Gardiner KM et al. Multinational Evaluation of Mycophenolic Acid, Tacrolimus, Cyclosporin, Sirolimus, and Everolimus Utilization. 2016 Ann. Transplant. pmid:26729299
Tang JT et al. A Low Fixed Tacrolimus Starting Dose Is Effective and Safe in Chinese Renal Transplantation Recipients. 2018 Ann. Transplant. pmid:29735966
Abdel Halim M et al. Toxic tacrolimus blood levels with rifampin administration in a renal transplant recipient. 2010 Jan-Mar Ann. Transplant. pmid:20305320
Malinowski M et al. The influence of commonly used immunosuppressive drugs on the small bowel functions - a comparative experimental study. 2009 Apr-Jun Ann. Transplant. pmid:19487793